Research Frontiers Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarter ended March 31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 000-14893 RESEARCH FRONTIERS INCORPORATED (Exact name of registrant as specified in its charter) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted andposted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter periodthat the registrant was required to submit and post such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer☐ Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes☐No☒ Securities registered pursuant to Section 12(b) of the Act: Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: As of May7, 2026, there were outstanding 34,867,786 shares of Common Stock, par value $0.0001 per share. Condensed Consolidated Balance Sheets March 31, 2026 (Unaudited) and December 31, 20253Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 2025 (Unaudited)4Condensed Consolidated Statements of Shareholders’ Equity for the Three Months Ended March 31, 2026 and 2025(Unaudited)5Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 (Unaudited)6Notes to the Condensed Consolidated Financial Statements (Unaudited)7-13Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations14-16Item 3. Quantitative and Qualitative Disclosures About Market Risk17Item 4. Controls and Procedures17PART II - OTHER INFORMATIONItem 6. Exhibits18SIGNATURES192 RESEARCH FRONTIERS INCORPORATEDCondensed Consolidated Statements of Operations(Unaudited) RESEARCH FRONTIERS INCORPORATEDCondensed Consolidated Statements of Shareholders’ Equity(Unaudited) For the three months ended March 31, 2026 and 2025 RESEARCH FRONTIERS INCORPORATEDCondensed Consolidated Statements of Cash Flows(Unaudited) RESEARCH FRONTIERS INCORPORATEDNotes to Condensed Consolidated Financial StatementsMarch 31, 2026(Unaudited) Note 1. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generallyaccepted accounting principles (“GAAP”) for interim financial information and with the instructions to Rule 8-03 of Regulation S-X.Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In theopinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of anormal recurring nature. Operating results for the three months ended March 31, 2026 are not necessarily indicative of the results thatmay be expected for the fiscal year ending December 31, 2026. The condensed consolidated balance sheet as of December 31, 2025has been derived from the audited consolidated financial statements as of that date. For further information, refer to the consolidatedfinancial statements and footnotes thereto included in the Annual Report on Form 10-K relating to Research Frontiers Incorporated forthe fiscal year ended December 31, 2025. Note 2. Business Research Frontiers Incorporated (“Research Frontiers” or the “Company”) operates in a single business segment which is engaged inthe development and marketing of technology and devices to control the flow of light. Such devices, often referred to as “light valves”or suspend